Glenmark Pharma receives final approval for clindamycin phosphate foam from USFDA

Mumbai, Sep 21 : Pharma major, Glenmark Pharma on Tuesday said that it has received final approval from the United States Food & Drug Administration for clindamycin phosphate foam 1 %

Clindamycin phosphate foam is the generic version of evoclin foam of Mylan Pharmaceuticals Inc.

According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam market achieved annual sales of approximately USD12.0 million.

Clindamycin is used to treat severe acne in adults and children who are at least 12 years old.


Please enter your comment!
Please enter your name here